Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome

Niraj Shenoy, Nishanth Vallumsetla, Eliezer Rachmilewitz, Amit Verma, Yelena Ginzburg

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal bone marrow disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and potential for malignant transformation. Lower/intermediate-risk MDSs are associated with longer survival and high red blood cell (RBC) transfusion requirements resulting in secondary iron overload. Recent data suggest that markers of iron overload portend a relatively poor prognosis, and retrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival in transfusion-dependent MDS patients. New data provide concrete evidence of iron's adverse effects on erythroid precursors in vitro and in vivo. Renewed interest in the iron field was heralded by the discovery of hepcidin, the main serum peptide hormone negative regulator of body iron. Evidence from β-thalassemia suggests that regulation of hepcidin by erythropoiesis dominates regulation by iron. Because iron overload develops in some MDS patients who do not require RBC transfusions, the suppressive effect of ineffective erythropoiesis on hepcidin may also play a role in iron overload. We anticipate that additional novel tools for measuring iron overload and a molecular-mechanism-driven description of MDS subtypes will provide a deeper understanding of how iron metabolism and erythropoiesis intersect in MDSs and improve clinical management of this patient population.

Original languageEnglish (US)
Pages (from-to)873-881
Number of pages9
JournalBlood
Volume124
Issue number6
DOIs
StatePublished - Aug 7 2014

Fingerprint

Iron Overload
Myelodysplastic Syndromes
Chelation
Iron
Hepcidins
Erythropoiesis
Erythrocyte Transfusion
Blood
Chelation Therapy
Thalassemia
Survival
Peptide Hormones
Hematopoiesis
Bone Marrow
Metabolism
Serum
Bone
Population
Cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. / Shenoy, Niraj; Vallumsetla, Nishanth; Rachmilewitz, Eliezer; Verma, Amit; Ginzburg, Yelena.

In: Blood, Vol. 124, No. 6, 07.08.2014, p. 873-881.

Research output: Contribution to journalArticle

Shenoy, Niraj ; Vallumsetla, Nishanth ; Rachmilewitz, Eliezer ; Verma, Amit ; Ginzburg, Yelena. / Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. In: Blood. 2014 ; Vol. 124, No. 6. pp. 873-881.
@article{92941866e10244f4a6f3bb546da465f0,
title = "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome",
abstract = "Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal bone marrow disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and potential for malignant transformation. Lower/intermediate-risk MDSs are associated with longer survival and high red blood cell (RBC) transfusion requirements resulting in secondary iron overload. Recent data suggest that markers of iron overload portend a relatively poor prognosis, and retrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival in transfusion-dependent MDS patients. New data provide concrete evidence of iron's adverse effects on erythroid precursors in vitro and in vivo. Renewed interest in the iron field was heralded by the discovery of hepcidin, the main serum peptide hormone negative regulator of body iron. Evidence from β-thalassemia suggests that regulation of hepcidin by erythropoiesis dominates regulation by iron. Because iron overload develops in some MDS patients who do not require RBC transfusions, the suppressive effect of ineffective erythropoiesis on hepcidin may also play a role in iron overload. We anticipate that additional novel tools for measuring iron overload and a molecular-mechanism-driven description of MDS subtypes will provide a deeper understanding of how iron metabolism and erythropoiesis intersect in MDSs and improve clinical management of this patient population.",
author = "Niraj Shenoy and Nishanth Vallumsetla and Eliezer Rachmilewitz and Amit Verma and Yelena Ginzburg",
year = "2014",
month = "8",
day = "7",
doi = "10.1182/blood-2014-03-563221",
language = "English (US)",
volume = "124",
pages = "873--881",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome

AU - Shenoy, Niraj

AU - Vallumsetla, Nishanth

AU - Rachmilewitz, Eliezer

AU - Verma, Amit

AU - Ginzburg, Yelena

PY - 2014/8/7

Y1 - 2014/8/7

N2 - Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal bone marrow disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and potential for malignant transformation. Lower/intermediate-risk MDSs are associated with longer survival and high red blood cell (RBC) transfusion requirements resulting in secondary iron overload. Recent data suggest that markers of iron overload portend a relatively poor prognosis, and retrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival in transfusion-dependent MDS patients. New data provide concrete evidence of iron's adverse effects on erythroid precursors in vitro and in vivo. Renewed interest in the iron field was heralded by the discovery of hepcidin, the main serum peptide hormone negative regulator of body iron. Evidence from β-thalassemia suggests that regulation of hepcidin by erythropoiesis dominates regulation by iron. Because iron overload develops in some MDS patients who do not require RBC transfusions, the suppressive effect of ineffective erythropoiesis on hepcidin may also play a role in iron overload. We anticipate that additional novel tools for measuring iron overload and a molecular-mechanism-driven description of MDS subtypes will provide a deeper understanding of how iron metabolism and erythropoiesis intersect in MDSs and improve clinical management of this patient population.

AB - Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal bone marrow disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and potential for malignant transformation. Lower/intermediate-risk MDSs are associated with longer survival and high red blood cell (RBC) transfusion requirements resulting in secondary iron overload. Recent data suggest that markers of iron overload portend a relatively poor prognosis, and retrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival in transfusion-dependent MDS patients. New data provide concrete evidence of iron's adverse effects on erythroid precursors in vitro and in vivo. Renewed interest in the iron field was heralded by the discovery of hepcidin, the main serum peptide hormone negative regulator of body iron. Evidence from β-thalassemia suggests that regulation of hepcidin by erythropoiesis dominates regulation by iron. Because iron overload develops in some MDS patients who do not require RBC transfusions, the suppressive effect of ineffective erythropoiesis on hepcidin may also play a role in iron overload. We anticipate that additional novel tools for measuring iron overload and a molecular-mechanism-driven description of MDS subtypes will provide a deeper understanding of how iron metabolism and erythropoiesis intersect in MDSs and improve clinical management of this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84905748509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905748509&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-03-563221

DO - 10.1182/blood-2014-03-563221

M3 - Article

C2 - 24923296

AN - SCOPUS:84905748509

VL - 124

SP - 873

EP - 881

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -